Reason ferritin in low in body 23 y old girl its circumstances
causes of low ferritin young women 23 year old iron deficiency circumstances
ferritin iron deficiency young women causes
iron deficiency anemia low ferritin causes pathophysiology diagram

A multi-panel pathophysiology infographic illustrating the main causes of acquired sideroblastic anemia through mitochondrial dysfunction. The central diagram depicts an erythroblast surrounded by three key impaired processes: Heme biosynthesis, Mitochondrial protein synthesis, and Fe/S (iron-sulfur) cluster biosynthesis. Ten surrounding panels detail specific etiologies including Hypothermia, SF3B1 mutation (Myelodysplastic Syndrome), Alcohol, Lead intoxication, Isoniazid, Copper deficiency/Zinc excess, Pyrazinamide, Pyridoxine (Vitamin B6) deficiency, Linezolid, and Chloramphenicol. Each panel uses molecular models to show specific inhibitory sites: for example, the inhibition of ALA-synthase by lead and vitamin B6 deficiency, or the disruption of the mitochondrial ribosome (30S and 50S subunits) by antibiotics like linezolid. The visual highlights how diverse toxic, nutritional, and genetic factors converge on mitochondrial metabolism, leading to iron overload in erythroblasts and the subsequent formation of ring sideroblasts.

This pathophysiology diagram illustrates the multifactorial causes and consequences of anemia in patients with heart failure (HF) and a left ventricular assist device (LVAD). The top section identifies contributors to anemia, including chronic gastrointestinal (GI) bleeding secondary to aspirin use, systemic anticoagulation, arteriovenous (AV) malformations, and von Willebrand disease. Other contributing factors shown are uremic gastritis, iron (Fe2+) malabsorption, and persistent right ventricular failure. Central to the diagram is the manifestation of anemia (defined as Hemoglobin < 12 g/dL), which correlates with elevated creatinine, decreased albumin, and increased mortality. The diagram also highlights therapeutic interventions such as erythropoiesis-stimulating agents (ESAs), aspirin-free antithrombotic management, omega-3 fatty acids, and low-intensity anticoagulation. Successful therapy is depicted as leading to normal red blood cell (RBC) counts, resolution of heart failure symptoms, and reduced mortality. The role of erythropoietin (EPO) is also noted in the context of LVAD-related anemia management.

This pathophysiology diagram illustrates the relationship between iron metabolism, macrophage polarization, and tumor growth within the tumor microenvironment (TME). A central cellular cluster depicts cancer cells (light orange), M1 macrophages (light blue, smooth), and M2 macrophages (purple, spiky). A vertical gradient represents iron concentration, influenced by 'Tumor iron influx' (bottom, associated with nanoparticles and anti-CD47) and 'Tumor iron efflux' (top, associated with chelation and anti-CSF1R). The diagram categorizes the TME into three metabolic regimes. 1) Low iron: favors M2 macrophages, characterized by increased ferroportin, lipocalin 2, and transferrin receptor but reduced ferritin, leading to reduced tumor growth. 2) Intermediate iron: characterized by 'iron-addicted' cancer cells with low ferroportin and high levels of ferritin, lipocalin 2, and transferrin receptor, which promotes tumor growth. 3) High iron: favors M1 macrophages, characterized by increased ferritin and reduced ferroportin, lipocalin 2, and transferrin receptor, resulting in reduced tumor growth. This educational infographic demonstrates how iron availability modulates immune cell phenotype and clinical outcomes in oncology.
| Condition | Mechanism |
|---|---|
| Celiac disease | Duodenal villous atrophy impairs absorption; very common in young women |
| H. pylori infection | Causes achlorhydria (low stomach acid), reducing Fe³+ → Fe²+ conversion; also causes ulcer bleeding |
| Inflammatory bowel disease (Crohn's/UC) | Mucosal damage + chronic GI blood loss |
| Autoimmune gastritis | Impairs iron and later B12 absorption |
| Bariatric surgery | Up to 50% of post-bariatric patients become iron deficient |
| Proton pump inhibitors / antacids | Reduce stomach acid needed for iron conversion |
| Category | Specific Cause |
|---|---|
| Blood loss | Heavy periods, GI bleeding, blood donation |
| Diet | Vegetarian/vegan, calorie restriction, poor iron intake |
| Malabsorption | Celiac disease, H. pylori, IBD, low stomach acid, PPI use |
| Increased demand | Pregnancy, breastfeeding, intense exercise |
| Hormonal/metabolic | Hypothyroidism, obesity (elevated hepcidin) |
Sources: Goldman-Cecil Medicine (Iron Deficiency chapter), Tietz Textbook of Laboratory Medicine, Symptom to Diagnosis (4th Ed.), Franciscan Health, Nebraska Medicine
Tyroid 2.29 in same patient
TSH 2.29 normal range interpretation young woman thyroid function
| TSH Zone | Range | This Patient |
|---|---|---|
| Hyperthyroid | < 0.4 mIU/L | No |
| Normal (euthyroid) | 0.4 - 4.0 mIU/L | Yes - 2.29 |
| Subclinical hypothyroid | 4.0 - 10 mIU/L | No |
| Overt hypothyroidism | > 10 mIU/L | No |